

**1. REM-Schlafverhaltensstörung (RBD) bei Parkinson-Erkrankung**

**M.-L. Muntean, F. Sixel-Döring, C. Trenkwalder**

Literatur:

1. Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. *Sleep* 1986; 9: 293–308
2. American Academy of Sleep Medicine. REM sleep behavior disorder. In: international classification of sleep disorders, Darien, IL: American Academy of Sleep Medicine 2014; 3: 246–53
3. Nalamalapu U, Goldberg R, DiPhillipo M, FryJM. Behaviors simulating REM behaviour disorder in patients with severe obstructive sleep apnea. *Sleep res* 1996; 25: 311
4. Provini F, Plazzi G, Tinuper P et al. Nocturnal frontal lobe epilepsy. A clinical and polygraphic overview of 100 consecutive cases. *Brain* 1999; 122: 1017–1031
5. Rechtschaffen A, Kales A, editors. Los Angeles: Brain Information Service/Brain Research Institute, University of California; 1968. A manual of standardized terminology, techniques and scoring system of sleep stages in human subjects.
6. Sixel-Döring F, Muntean ML. REM Sleep Behavior Disorder in neurodegenerative diseases. *Klin Neurophysiol* 2016; 47: 125–130
7. Frauscher B, Iranzo A, Gaig C et al. for the SINBAR Group. Normative EMG values during REM sleep for the diagnosis of REM sleep behavior disorder. *SLEEP* 2012; 35: 835–47
8. Sixel-Döring F, Schweitzer M, Mollenhauer B, Trenkwalder C. Intraindividual variability of REM sleep behaviour disorder in Parkinson's disease: a comparative assessment using a new REM sleep behaviour disorder severity scale (RBDSS) for clinical routine. *J ClinSleepMed* 2011; 7: 75–80
9. Stiasny-Kolster K, Mayer G, Schäfer S et al. The REM sleep behavior disorder screening questionnaire – a new diagnostic instrument. *Mov Disord* 2007; 22: 2386–2393
10. Li SX, Wing YK, Lam SP et al. Validation of a new REM sleep behavior disorder question. *Sleep Med* 2010; 11(1): 43–48
11. Boeve BF, Molano JR, Ferman TJ et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in a community-based sample. *J Clin Sleep Med* 2013; 9: 475–480
12. Frauscher B, Ehrmann L, Zamarian L et al. Validation of the Innsbruck REM sleep behaviour disorder inventory. *MovDisord* 2012; 27: 1673–1678
13. Postuma RB, Arnulf I, Hogl B et al. A single question screen for rapid eye movement sleep behavior disorder: a multicenter validation study. *MovDisord* 2012; 27: 913–916
14. Frauscher B, Högl B. Quality control for diagnosis of REM sleep behavior disorder: criteria, questionnaires, video, and polysomnography. In: Videnovic A, Högl B (eds) *Disorders of sleep and circadian rhythms in Parkinson's disease*, Springer Wien 2015; 1: 145–158
15. Stiasny-Kolster K, Sixel-Döring F, Trenkwalder C et al. Diagnostic value of the REM sleep behavior disorder screening questionnaire in Parkinson's disease. *SleepMed* 2015; 16: 186–189
16. Halsband CA, Zapf A, Sixel-Döring F et al. The REM Sleep Behavior Disorder Screening Questionnaire is not Valid in De Novo Parkinson's Disease. *MOVEMENT DISORDERS CLINICAL PRACTICE* 2018; 5(2): 171–176
17. Boeve BF, Silber MH, Saper CB et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. *Brain* 2007; 130: 2770–88
18. Brooks PL, Peever JH. Impaired GABA and glycine transmission triggers cardinal features of rapid eye movement sleep behaviour disorder in mice. *J Neurosci* 2011; 31: 7111–21
19. Krenzer M, Anaclet C, Vetrivelan R. Brainstem and spinal cord circuitry regulating REM sleep and muscle atonia. *PLoS One* 2011; 6: e24998
20. Lu J, Shermann D, Devor M, Saper CB. A putative flip-flop switch for control of REM sleep. *Nature* 2006; 441: 589–94
21. Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81 % of older males initially diagnosed with idiopathic REM sleep behavior disorder (RBD): 16 year update on a previously reported series. *Sleep Med* 2013; 14: 744–8
22. Iranzo A, Molinuevo JL, Santamaria J et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. *Lancet Neurol* 2006; 5: 572–7

23. Postuma RB et al on behalf of REM Sleep Behavior Disorder Study Group Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. *Brain* 2019 doi:10.1093/brain/awz030
24. Knudsen K, Fedorova TD, Hansen AK et al. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. *Lancet Neurol* 2018; 17(7): 618–628
25. Stiasny-Kolster K, Doerr Y, Möller JC et al. Combination of “idiopathic” REM sleep behaviour disorder and olfactory dysfunction as possible indicator  $\alpha$ -synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. *Brain* 2005; 128: 126–13725
26. Mollenhauer B, Trautmann E, Sixel-Döring F et al. Non-motor findings and diagnostic results in de novo Parkinson’s disease subjects of the DeNopa Study. *Neurology* 2013; 81: 1226–34
27. Sixel-Döring F, Trautmann E, Trenkwalder C, Mollenhauer B. REM sleep behavioural events (RBE): a new marker for neurodegeneration in early Parkinson’s disease? *Sleep* 2014; 37: 431–8
28. Kumru H, Santamaria J, Tolosa E, Iranzo A. Relation between subtype of Parkinson’s disease and REM sleep behavior disorder. *Sleep Med* 2007; 8:779–83
29. Sixel-Döring F, Zimmermann J, Wegener A et al. The evolution of REM sleep behavior disorder in early Parkinson’s disease. *Sleep* 2016; 39(9): 1737–4
30. Sixel-Döring F, Zimansky LMK, Muntean ML et al. REM sleep behavior disorder and REM sleep without atonia as progression markers in Parkinson’s disease patients: a report from the DeNoPa cohort. MDS Congress, Nice 2019, Poster
31. Sixel-Döring F, Trautmann E, Mollenhauer B, Trenkwalder C. Associated factors for REM sleep behavior disorder in Parkinson’s disease. *Neurology* 2011; 77: 1048–54
32. Aurora et al & the Standards of Practice Committee. Best Practice Guide for the Treatment of REM Sleep Behaviour Disorder (RBD). *J Clin Sleep Med* 2010; 6: 85–95
33. Kunz D, Mahlberg R. A tow-part, double-blind, placebocontrolled trial of exogenous melatonin in REM sleep behaviour disorder. *J Sleep Res.* 2010; 19: 591–6
34. Jung Y, St Louis EK. Treatment of REM Sleep Behavior Disorder. *Curr Treat Options Neurol* 2016; 18(11): 50

## 2. Stellenwert der Cannabinoide in der Medizin

**K. Müller-Vahl, F. Grotenhermen**

Literatur:

1. Fankhauser M. Haschisch als Medikament: Zur Bedeutung von cannabis sativa in der westlichen Medizin. Liebefeld (Schweiz): SGGP, Schweizerischer Apothekerverein 2003
2. Loewe S. Cannabiswirkstoffe und Pharmakologie der Cannabinole. *Arch Exp Pathol Pharmacol* 1950; 211: 175–193
3. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. *J Am Chem Soc* 1964; 86: 1646–1647
4. Maccarrone M, Bab I, Bíró T, Cabral GA, Dey SK, DiMarzo V, et al. Endocannabinoid signaling at the periphery: 50 years after THC. *Trends Pharmacol Sci* 2015; 36: 277–296
5. Mechoulam R, Parker LA. The endocannabinoid system and the brain. *Annu Rev Psychol* 2013; 64: 21–47
6. Grotenhermen F, Berger M, Gebhardt K. Cannabidiol (CBD): Ein cannabishaltiges Compendium. Solothurn (Schweiz):Nachtschatten Verlag 2015
7. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. *JAMA* 2015; 313: 2456–2473
8. Curran V, Morgan CJA. Desired and undesired effects of cannabis on the human mind and psychological well-being. In: Pertwee R (eds.). *Handbook of Cannabis*. Oxford: Oxford University Press 2014, 647–660

9. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. *Lancet* 2007; 370: 319–328
10. Grotenhermen F. Non-psychological adverse effects. In: Pertwee R (eds.). *Handbook of Cannabis*. Oxford: Oxford University Press; 2014. 674–691
11. Vandrey RG, Budney AJ, Hughes JR, Liguori A. A withinsubject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances. *Drug Alcohol Depend* 2008; 92: 48–54
12. Grotenhermen F. Cannabinoids. *Curr Drug Targets CNS Neurol Disord* 2005; 4: 507–530
13. Jiang R, Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. *Drug Metab Pharmacokinet* 2013; 28: 332–338
14. Merkblatt des Bundesministeriums für Verkehr und digitale Infrastruktur 2015. [http://cannabis-med.org/nis/data/file/bundesverkehrsministerium\\_fuehrerschein\\_2015.pdf](http://cannabis-med.org/nis/data/file/bundesverkehrsministerium_fuehrerschein_2015.pdf)

### **3. Die Aufmerksamkeitsdefizits-/Hyperaktivitätsstörung als 24h-Störung behandeln**

#### **E. Ahlers**

Literatur:

1. Faraone SV et al. Attention-deficit/hyperactivity disorder. *Nat Rev Dis Primers* 1 2015; 15020
2. Wender PH, *Attention-Deficit Hyperactivity Disorder in Adults*. Oxford University Press Inc 1998; Reprint; ISBN-10: 0195119223, ISBN-13: 978-0195119220
3. Instanes JT et al. Adult ADHD and Comorbid Somatic Disease: A Systematic Literature Review 2018; 22(3): 203–228. Published online 2016 Sep 1. doi: 10.1177/1087054716669589
4. Jain R, Jain S, Montano CB. *Prim Care Companion CNS Disord* 2017; 19(5): 17nr02153 <https://doi.org/10.4088/PCC.17nr02153>
5. Díaz-Román A, Mitchell R, Cortese S. Sleep in adults with ADHD: Systematic review and meta-analysis of subjective and objective studies. *Neurosci Biobehav Rev*. 2018; 89: 61–71. doi: 10.1016/j.neubiorev.2018.02.014
6. Blesch L, Breese McCoy SJ. Obstructive Sleep Apnea Mimics Attention Deficit Disorder. *J Atten Disord* 2016; 20(1): 41–2. doi: 10.1177/1087054713479664
7. Konofal E, Lecendreux M, Cortese S. Sleep and ADHD. *Sleep medicine* 2010; 11: 652–882
8. Cortese S, Faraone SV, Konofal E, Lecendreux M. Sleep in children with attentiondeficit/hyperactivity disorder: meta-analysis of subjective and objective studies. *Journal of the American Academy of Child and Adolescent Psychiatry* 2009; 48: 894–908
9. Yoon SY, Jain U, Shapiro C. Sleep in attention-deficit/hyperactivity disorder in children and adults: past, present, and future. *Sleep Med Rev* 2012; 16(4): 371–88. doi: 10.1016/j.smr.2011.07.001
10. Bergwerff CE, Luman M, Oosterlaan J. No objectively measured sleep disturbances in children with attention-deficit/hyperactivity disorder. *J Sleep Res* 2016; 25(5): 534–540. doi: 10.1111/jsr.12399. Epub 2016 Mar 29
11. Baglioni et al. *Psychological Bulletin: 2016 American Psychological Association* 2016; Vol. 142, No. 9, 969–990 0033–2909/16/\$12.00; <http://dx.doi.org/10.1037/bul0000053>
12. Miano S, Esposito M, Foderaro G et al. Sleep-Related Disorders in Children with Attention-Deficit Hyperactivity Disorder: Preliminary Results of a Full Sleep Assessment Study. *CNS Neurosci Ther* 2016; 22(11): 906–914. doi: 10.1111/cns.12573
13. Luo et al. *Front. A Review of Heterogeneity in Attention Deficit/Hyperactivity Disorder (ADHD)*. *Hum. Neurosci* 2019; <https://doi.org/10.3389/fnhum.2019.00042>

14. Cortese S, Angriman M. Treatment of sleep disorders in youth with ADHD: what is the evidence from randomised controlled trials and how should the field move forward? *Expert Rev Neurother* 2017; 17(6): 525–527. doi: 10.1080/14737175.2017.1311789
15. Hobson S, Davie M, Farquhar M. Fifteen-minute consultation: Managing sleep problems in children and young people with ADHD. *Arch Dis Child Educ Pract Ed* 2017; doi: 10.1136/archdischild-2017-313583
16. Becker SP, Langberg JM, Evans SW. Sleep problems predict comorbid externalizing behaviors and depression in young adolescents with attention-deficit/hyperactivity disorder. *Eur Child Adolesc Psychiatry* 2015; 24(8): 897–907. doi: 10.1007/s00787-014-0636-6

#### 4. Geschichte von Methylphenidat in der Behandlung des ADHS

**M. Weih**

Literatur:

1. Edeleanu L: [Über einige Derivate der Phenylmethacrylsäure und der Phenylisobuttersäure.](#) In: *Berichte der Deutschen chemischen Gesellschaft zu Berlin*; 20. Jg. 1887; Band 3: 616–622
2. <https://de.wikipedia.org/wiki/Adrenalin>, Zugriff 18.2. um 17:27 Uhr
3. <https://de.wikipedia.org/wiki/Methylphenidat>, Zugriff 12.2.2019 um 18:40 Uhr
4. <https://de.wikipedia.org/wiki/Ephedrin>, Zugriff 24.2.19 um 19:22 Uhr
5. Guttman E. Some Psychiatric Observations in Arterial Hypertension; *Proceedings of the Royal Society of Medicine*, Vol XXIX, 1936; 57
6. C. Bradlez. The Behavior of Children Receiving Benzedrine. In: *American Journal of Psychiatry*, November 1937; 94: 577–581
7. <https://patentimages.storage.googleapis.com/c6/e7/ae/f60c5e43fc7b23/US2507631.pdf>
8. Meier R, Gross F, Tripod J. Ritalin, eine neuartige synthetische Verbindung mit spezifischer zentral erregender Wirkungskomponente, *Klin. Wochenschrift* 1954; 32: 44 – 50
9. [https://www.adhspedia.de/wiki/Leandro\\_Panizzon](https://www.adhspedia.de/wiki/Leandro_Panizzon), Zugriff am 12.2.19 um 18:59 Uhr